Consistent with our results, high immunologic capacity to produce IFN-γ is therefore likely to be beneficial for the clinical outcome of lung cancer patients, with a lower ex vivo stimulated response predicting a poor outcome. The gene discussed is IFNG; the disease is lung cancer.